More Articles Back to Article
Lymphoma treatment gains conditional approval in Europe
Roche's Polivy, or polatuzumab vedotin, an antibody-drug conjugate used in combination with bendamustine plus MabThera, or rituximab, received conditional approval from the European Commission to treat adults with relapsed or refractory diffuse large B-cell lymphoma who are ineligible for a hematopoietic stem cell transplant. Seeking Alpha (1/21)
Read full article now.
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!